Evolution Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Evolution Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$88.5K	–	123
2023 Q1	$88.5K	Buy	+10,000	New	+$98.9K	0.02%	114
2022 Q4	–	Sell	-10,000	Closed	-$81K	–	126
2022 Q3	$81K	Hold	10,000	–	–	0.02%	106
2022 Q2	$75K	Hold	10,000	–	–	0.02%	112
2022 Q1	$94K	Buy	+10,000	New	+$83.5K	0.02%	118
2021 Q4	–	Sell	-230	Closed	-$2K	–	575
2021 Q3	$2K	Hold	230	–	–	﹤0.01%	655
2021 Q2	$2K	Hold	230	–	–	﹤0.01%	623
2021 Q1	$3K	Hold	230	–	–	﹤0.01%	614
2020 Q4	$2K	Hold	230	–	–	﹤0.01%	566
2020 Q3	$2K	Hold	230	–	–	﹤0.01%	566
2020 Q2	$3K	Hold	230	–	–	﹤0.01%	451
2020 Q1	$2K	Sell	230 -582	-72%	-$5.96K	﹤0.01%	296
2019 Q4	$8K	Buy	+812	New	+$7.25K	﹤0.01%	340
2019 Q1	–	Sell	-50	Closed	-$882	–	148
2018 Q4	$1K	Buy	+50	New	+$1.02K	﹤0.01%	139

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Evolution Wealth Advisors's TEVA Position: Q2 2023 in Review

Evolution Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 10,000 shares — an estimated $88.5K sold.

Evolution Wealth Advisors first reported a position in TEVA in Q4 2018 and held it in 13 quarters. The position peaked at $94K in Q1 2022. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

Evolution Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Evolution Wealth Advisors sold 10,000 Teva Pharmaceuticals shares in Q2 2023, an estimated $88.5K.
Evolution Wealth Advisors first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 13 quarters.
Evolution Wealth Advisors's Teva Pharmaceuticals position peaked at $94K in Q1 2022.
428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Evolution Wealth Advisors's 13F filing for Q2 2023, filed 17 Jul 2023.